Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.70 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | OGG1 | O15527 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4682432 | 0.84 | HPGD (0.72) | HPGDTRPA1LMNAHTTALDH1A1 | |
| SCHEMBL1163995 | 0.82 | HPGD (0.53) | HPGDTRPA1CA12MMP2CA14 | |
| SCHEMBL1923460 | 0.82 | CA12 (0.54) | HPGDTRPA1CA12MMP2CA14 | |
| SCHEMBL1164028 | 0.82 | TRPA1 (0.55) | HPGDTRPA1CA12MMP2CA14 | |
| SCHEMBL12877951 | 0.82 | HPGD (0.70) | HPGDTRPA1LMNAHTTALDH1A1 | |
| SCHEMBL4682438 | 0.82 | HPGD (0.70) | HPGDTRPA1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4679490 | 0.82 | HPGD (1.00) | HPGDTRPA1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4679419 | 0.81 | HPGD (0.69) | HPGDTRPA1CA12LMNAALDH1A1 | |
| Chloral Hydrate SCHEMBL6624035 | 0.79 | HPGD (0.65) | HPGDTRPA1CA12LMNAALDH1A1 | |
| SCHEMBL10805990 | 0.79 | HPGD (0.65) | HPGDLMNAHTTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376452-A1 | 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof | ENANTA PHARM INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-12384753-B2 | 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4387603-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | Enanta Pharmaceuticals, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-118103038-A | 17 Beta-hydroxysteroid dehydrogenase 13 inhibitors and methods of use thereof | 英安塔制药有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2023023310-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023023310-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20120190694-A1 | SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | ALLERGAN, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| WO-2011028927-A1 | SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | ALLERGAN, INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011028927-A1 | SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | ALLERGAN, INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20110039866-A1 | SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | ALLERGAN, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039866-A1 | SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | ALLERGAN, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039866-A1 | SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | ALLERGAN, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| WO-2010019646-A1 | SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONISTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019646-A1 | SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONISTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041715-A1 | SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONISTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041715-A1 | SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONISTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041715-A1 | SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONISTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190694-A1 | SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | S1PR3, S1PR1, S1PR2 | HPGD 3667/4885TRPA1 1127/4885CA12 4826/4885 |
| US-20100041715-A1 | SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONISTS AND METHODS FOR USE THEREOF | S1PR1, S1PR2, S1PR3 | HPGD 2890/4885TRPA1 932/4885CA12 4361/4885 |
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | HSD17B1, HSD17B13, HSD17B3 | HPGD 43/4885TRPA1 4883/4885CA12 1212/4885 |
| US-20250376452-A1 | 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof | HSD17B1, HSD17B13, HSD17B3 | HPGD 43/4885TRPA1 4883/4885CA12 1212/4885 |
| US-20110039866-A1 | SELECTIVE SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | S1PR3, S1PR1, S1PR2 | HPGD 3667/4885TRPA1 1127/4885CA12 4826/4885 |
| US-12384753-B2 | 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof | HSD17B1, HSD17B13, HSD17B3 | HPGD 43/4885TRPA1 4883/4885CA12 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.